Advanced search
1 file | 2.66 MB

Adjuvant or neoadjuvant chemotherapy in minimal N2 stage IIIA nonsmall cell lung cancer

SOFIE DE CRAENE (UGent) , Veerle Surmont (UGent) and Jan Van Meerbeeck (UGent)
(2010) CURRENT OPINION IN ONCOLOGY. 22(2). p.102-111
Author
Organization
Abstract
Purpose of review: In the last decade, numerous randomized trials have evaluated the benefit of (neo-)adjuvant chemotherapy in nonsmall cell lung cancer. This article will review the recent data on perioperative chemotherapy in stage III A-N2 nonsmall cell lung cancer and future research opportunities are presented. Recent findings: Four retrospective series, two phase 2 and four phase 3 trials in the neoadjuvant setting and one retrospective series, two phase 2 trials and two phase 3 trials in the adjuvant setting are retrieved and discussed. Summary: The available evidence does not allow to change the current recommendation regarding the management of patients presenting with biopsy-proven clinical stage IIIA-N2 nonsmall cell lung cancer: their preferred treatment is chemoradiotherapy. Surgery with neoadjuvant or adjuvant chemotherapy is not proven superior to radiotherapy. The patient occasionally presenting with unforeseen pN2 despite adequate preoperative mediastinal staging should be offered adjuvant cisplatin-based chemotherapy and possibly postoperative radiotherapy.
Keywords
chemotherapy, combined modality, radiotherapy, stage IIIA-N2, surgery, POSITRON-EMISSION-TOMOGRAPHY, INDUCTION CHEMOTHERAPY, NEEDLE-ASPIRATION, PHASE-III, TRIAL, THERAPY, SURGERY, CHEMORADIOTHERAPY, CARBOPLATIN, EXPERIENCE

Downloads

  • (...).pdf
    • full text
    • |
    • UGent only
    • |
    • PDF
    • |
    • 2.66 MB

Citation

Please use this url to cite or link to this publication:

Chicago
DE CRAENE, SOFIE, Veerle Surmont, and Jan Van Meerbeeck. 2010. “Adjuvant or Neoadjuvant Chemotherapy in Minimal N2 Stage IIIA Nonsmall Cell Lung Cancer.” Current Opinion in Oncology 22 (2): 102–111.
APA
DE CRAENE, S., Surmont, V., & Van Meerbeeck, J. (2010). Adjuvant or neoadjuvant chemotherapy in minimal N2 stage IIIA nonsmall cell lung cancer. CURRENT OPINION IN ONCOLOGY, 22(2), 102–111.
Vancouver
1.
DE CRAENE S, Surmont V, Van Meerbeeck J. Adjuvant or neoadjuvant chemotherapy in minimal N2 stage IIIA nonsmall cell lung cancer. CURRENT OPINION IN ONCOLOGY. 2010;22(2):102–11.
MLA
DE CRAENE, SOFIE, Veerle Surmont, and Jan Van Meerbeeck. “Adjuvant or Neoadjuvant Chemotherapy in Minimal N2 Stage IIIA Nonsmall Cell Lung Cancer.” CURRENT OPINION IN ONCOLOGY 22.2 (2010): 102–111. Print.
@article{923187,
  abstract     = {Purpose of review: In the last decade, numerous randomized trials have evaluated the benefit of (neo-)adjuvant chemotherapy in nonsmall cell lung cancer. This article will review the recent data on perioperative chemotherapy in stage III A-N2 nonsmall cell lung cancer and future research opportunities are presented.
Recent findings: Four retrospective series, two phase 2 and four phase 3 trials in the neoadjuvant setting and one retrospective series, two phase 2 trials and two phase 3 trials in the adjuvant setting are retrieved and discussed.
Summary: The available evidence does not allow to change the current recommendation regarding the management of patients presenting with biopsy-proven clinical stage IIIA-N2 nonsmall cell lung cancer: their preferred treatment is chemoradiotherapy. Surgery with neoadjuvant or adjuvant chemotherapy is not proven superior to radiotherapy. The patient occasionally presenting with unforeseen pN2 despite adequate preoperative mediastinal staging should be offered adjuvant cisplatin-based chemotherapy and possibly postoperative radiotherapy.},
  author       = {DE CRAENE, SOFIE and Surmont, Veerle and Van Meerbeeck, Jan},
  issn         = {1040-8746},
  journal      = {CURRENT OPINION IN ONCOLOGY},
  language     = {eng},
  number       = {2},
  pages        = {102--111},
  title        = {Adjuvant or neoadjuvant chemotherapy in minimal N2 stage IIIA nonsmall cell lung cancer},
  url          = {http://dx.doi.org/10.1097/CCO.0b013e328335c076},
  volume       = {22},
  year         = {2010},
}

Altmetric
View in Altmetric
Web of Science
Times cited: